Qiagen N.V. (NYSE:QGEN) Shares Purchased by Forsta AP Fonden

Key Points

• Forsta AP Fonden increased its holdings in Qiagen N.V. by 185.8% during Q1, owning a total of 29,368 shares valued at approximately $1,179,000.
• Analysts have raised their target prices for Qiagen, with Bank of America setting a new target of $53.00 and UBS Group at $50.00, reflecting a mix of 'buy' and 'hold' ratings.
• Qiagen recently reported $0.60 EPS for the quarter, meeting analysts' expectations, with revenues increasing by 7.7% year-over-year to $533.54 million.

Forsta AP Fonden boosted its holdings in Qiagen N.V. (NYSE:QGEN - Free Report) by 185.8% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 29,368 shares of the company's stock after buying an additional 19,093 shares during the period. Forsta AP Fonden's holdings in Qiagen were worth $1,179,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of QGEN. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Qiagen during the fourth quarter worth approximately $95,746,000. Deutsche Bank AG boosted its holdings in Qiagen by 57.5% in the first quarter. Deutsche Bank AG now owns 4,491,131 shares of the company's stock valued at $180,319,000 after acquiring an additional 1,639,621 shares during the last quarter. Marshall Wace LLP increased its position in Qiagen by 138.1% during the 4th quarter. Marshall Wace LLP now owns 1,428,940 shares of the company's stock worth $63,701,000 after purchasing an additional 828,688 shares in the last quarter. Freestone Grove Partners LP acquired a new stake in Qiagen during the 4th quarter worth approximately $23,584,000. Finally, Envestnet Asset Management Inc. acquired a new stake in Qiagen during the 1st quarter worth approximately $13,463,000. Institutional investors and hedge funds own 70.00% of the company's stock.

Analyst Ratings Changes

A number of analysts recently issued reports on QGEN shares. Robert W. Baird increased their target price on shares of Qiagen from $42.00 to $43.00 and gave the stock a "neutral" rating in a research report on Monday, April 21st. Bank of America lifted their target price on shares of Qiagen from $50.00 to $53.00 and gave the company a "buy" rating in a report on Thursday, June 26th. UBS Group increased their target price on Qiagen from $48.00 to $50.00 and gave the company a "neutral" rating in a research note on Thursday, August 7th. Cowen reiterated a "hold" rating on shares of Qiagen in a research note on Thursday, August 7th. Finally, Barclays initiated coverage on Qiagen in a research note on Tuesday, June 24th. They issued an "overweight" rating and a $55.00 target price for the company. Eight research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $49.69.

Qiagen Trading Up 2.0%

Shares of NYSE QGEN opened at $48.98 on Wednesday. The stock's 50 day moving average price is $48.15 and its two-hundred day moving average price is $43.60. Qiagen N.V. has a 52-week low of $37.63 and a 52-week high of $51.88. The stock has a market capitalization of $10.89 billion, a P/E ratio of 28.94, a PEG ratio of 2.45 and a beta of 0.64. The company has a quick ratio of 1.35, a current ratio of 1.61 and a debt-to-equity ratio of 0.25.

Qiagen (NYSE:QGEN - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 EPS for the quarter, hitting analysts' consensus estimates of $0.60. The firm had revenue of $533.54 million during the quarter, compared to the consensus estimate of $523.97 million. Qiagen had a net margin of 18.30% and a return on equity of 14.77%. The firm's revenue was up 7.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.55 earnings per share. On average, analysts anticipate that Qiagen N.V. will post 2.26 earnings per share for the current fiscal year.

Qiagen Dividend Announcement

The business also recently disclosed a dividend, which was paid on Thursday, July 10th. Investors of record on Thursday, July 3rd were given a dividend of $0.25 per share. The ex-dividend date was Wednesday, July 2nd. This represents a yield of 52.0%. Qiagen's payout ratio is currently 14.79%.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.

Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen N.V. (NYSE:QGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.